Pharmaceuticals, Biotechnology and Life Sciences
Eli Lilly and Incyte Corporation scored a recommended approval of the 2-mg dose of a once-daily oral medication baricitinib from…
Eli Lilly and Incyte Corporation have won European Commission’s marketing authorisation for Olumiant (baricitinib) 4 mg and 2 mg film-coated tablets in Europe for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs).
Eli Lilly and Incyte Corporation have gotten positive opinion from European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
Eli Lilly and Company and Incyte Corporation announced positive topline results of RA-BEAM, the fourth successful Phase 3 study of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis.